Hans Moebius - Jun 2, 2023 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Role: Chief Medical Officer
Signature: /s/ Mark Worthington, Attorney-in-Fact for Hans Moebius
Stock symbol: ATHA
Transactions as of: Jun 2, 2023
Transactions value $: $29,352
Form type: 4
Date filed: 6/6/2023, 07:35 PM
Previous filing: Jan 23, 2023
Next filing: Jan 8, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ATHA	Common Stock	Award	$18.7K	+7.76K	+11.79%	$2.41	73.6K	May 18, 2023	Direct	F1, F2, F3
transaction	ATHA	Common Stock	Options Exercise	$10.6K	+7.88K	+10.71%	$1.35	81.5K	Jun 2, 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ATHA	Stock Option (Right to Buy)	Options Exercise	$0	-7.88K	-100%	$0.00^*	0	Jun 2, 2023	Common Stock	7.88K	$1.35	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of November 18, 2022 through May 18, 2023. This transaction is also exempt under Rule 16b-3(c).
F2	The Purchase Period ended May 18, 2023 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began November 18, 2022.
F3	In accordance with the ESPP, these shares were purchased based on 85% of the closing price on May 18, 2023.
F4	One-fourth of the shares subject to the option vested on June 1, 2020 and one-fourth of the shares subject to the option vest on each year thereafter.